Pharma Exclusives Pressreleases
Thermo Fisher Scientific’s Olink Platform Selected for World’s Largest Human Proteome Study
Friday, January 10, 2025Thermo Fisher Scientific Inc the world leader in serving science today announced the UK Biobank Pharma Proteomics Project UKBPPP has selected its Olink Explore Platform to support the worlds largest human proteomics study of its kind UKBPPP aims to a...
Bio-Techne Expands R&D Systems AI-Engineered Designer Protein Portfolio to Advance Cell Therapy and Regenerative Medicine
Friday, January 10, 2025BioTechne a global leader in life science tools and reagents today announced the launch of new designer proteins engineered using advanced Artificial Intelligence AI based design platforms and protein evolutionary workflows This expanded portfolio fr...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Wednesday, January 08, 2025Biomea Fusion Inc a clinicalstage biopharmaceutical company dedicated to discovering and developing oral covalent small molecules to improve the lives of patients with diabetes obesity and genetically defined cancers today announce compelling results...
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Tuesday, January 07, 2025Pfizer Inc invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla Chairman and Chief Executive Officer at the rd Annual JP Morgan Healthcare Conference on Monday January at am PST
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
Saturday, December 21, 2024Pfizer Inc announced that the US Food and Drug Administration FDA has approved BRAFTOVI encorafenib in combination with cetuximab marketed as ERBITUX and mFOLFOX fluorouracil leucovorin and oxaliplatin for the treatment of patients with metastatic c...
Bio-Techne Announces Biotherapeutic Characterization Strategic Co-marketing and Co-promotion Agreement
Friday, December 20, 2024BioTechne Corporation a leader in automated platforms for biotherapeutic characterization today announced a comarketing and copromotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterization and dev...
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
Friday, December 20, 2024Shuttle Pharmaceuticals Holdings Inc a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy RT today announced a sponsored research agreement with the Univer...
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody
Friday, December 20, 2024Merck known as MSD outside of the United States and Canada today announced the closing of the exclusive global license agreement for LM a novel investigational PDVEGF bispecific antibody from LaNova Medicines Ltd As previously announced Merck will de...
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
Friday, December 20, 2024Eton Pharmaceuticals Inc an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases today announced that it has completed its previously announced asset purchase of Increlex mecasermin injection from I...
Tonix Pharmaceuticals Announces FDA Acceptance of the New Drug Application (NDA) for TNX-102 SL for Fibromyalgia
Wednesday, December 18, 2024Tonix Pharmaceuticals Holding Corp today announced that the US Food and Drug Administration FDA has accepted the filing of its New Drug Application NDA for TNX SL cyclobenzaprine HCl sublingual tablets a mg nonopioid centrallyacting analgesic for th...
